Media-OutReach Newswire Triple agonist UBT251 showed a mean HbA1c reduction of up to 2.16% after 24 weeks in phase 2 trial in Chinese patients with type 2 diabetes
Media-OutReach Newswire Health2Sync and Novo Nordisk Pharma Korea, Ltd. Launch Smart Cap Mallya® for FlexTouch® Insulin Pens Integration in South Korea, Enhancing insulin administration via Digital Diabetes Care
Media-OutReach Newswire Zuellig Pharma Launches Lilly’s Innovative Obesity and Diabetes Medicine in Thailand